Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q2 2026 · 10-Q
Revenue—
Net Income$78.16M$78.16M+488.2% vs Q2 2025 EPS Diluted$1.84$1.84+493.5% vs Q2 2025 Operating Income-$2,766,000N/M Operating Cash Flowderived-$200,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Free Cash Flowderived-$202,000N/M ended Jun 30, 2026 · filed Aug 10, 2026 · 41 d after period end